Financial Performance - Total operating loss for 2021 was $60.7 million, up 80% from a loss of $33.7 million in 2020[315] - Net cash used in operating activities was $47.6 million in 2021, compared to $24.6 million in 2020, reflecting increased operating expenses[325] - The company reported a total other income of $6,000 in 2021, a 99% decrease from $451,000 in 2020[321] - The company incurred net cash used in investing activities of $3.3 million in 2021, primarily for laboratory equipment and office furnishings[326] - As of December 31, 2021, the company had an accumulated deficit of $393.5 million and cash and cash equivalents of $142.5 million[322] Expenses - Research and development expenses increased to $39.2 million in 2021 from $24.3 million in 2020, representing a 61% increase[315] - General and administrative expenses rose to $21.5 million in 2021 from $17.2 million in 2020, a 25% increase[319] Capital Resources - The company expects existing capital resources to fund operations into the second half of 2023[328] - The company entered into an ATM Equity Offering Sales Agreement with BofA for an aggregate offering price of up to $40 million, with no sales made to date[323] Stock-Based Compensation - The company measures the cost of stock-based compensation based on the grant-date fair value of the award, recognized over the vesting period[339] - The fair value of options granted is estimated using the Black-Scholes option pricing model, which involves significant estimates regarding expected term, stock price volatility, and risk-free interest rate[340] - There is inherent uncertainty in the company's forecasts and projections, which could materially affect stock-based compensation expense, net loss, and net loss per common stock amounts[341] Licensing and Agreements - The company has an exclusive license agreement with UW, which includes potential milestone payments of up to $10 million based on cumulative net sales of licensed products[334] Market Risk - As a "smaller reporting company," the company is not required to provide quantitative and qualitative disclosures about market risk[343]

neoleukin" Corporate Presentation November 2021 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 ________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ For the transition period from ________ to ________ Commission file number: 001-36327 __________________________________________________ Neoleukin Therapeutics, Inc. (Exact name of registrant as specified in its charter) __________________________________________________ Delaware 98-0542593 (State or other jurisdiction of incorporation or organization) FORM 10-Q __________________________ ...

neoleukin" THERAPEUTICS May 12, 2021 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ (I.R.S. Employer Identification No.) 188 East ...

Neoleukin Therapeutics, Inc. (NLTX) Q4 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief Executive Officer Robert Ho - Chief Financial Officer Daniel-Adriano Silva - Head of Research Carl Walkey - Senior Vice President of Corporate Development Umut Ulge - Vice President of Clinical Development Conference Call Participants Tyler Van Buren - Piper Sandler Arlinda Lee - Canaccord Genuity Operator Good morning and thank you for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Exact name of registrant as specified in its charter) _________________________ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) For the transition period from to Commission file number: 001-36327 _________________________ Neoleukin Therapeutics, Inc. (M ...

neoleukin™ Corporate Presentation January 2021 Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36327 Delaware 98-0542593 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No ...